Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Completed
Shire
Phase 2/Phase 3
2007-08-21
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase
II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral
modified-release hydrocortisone in comparison to conventional thrice-daily oral
hydrocortisone tablets in patients with adrenal insufficiency
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Terminated
Assistance Publique - Hôpitaux de Paris
Phase 3
2010-03-01
The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is
rapidly progressing worldwide and a substantial number of patients get severe H1N1 related
pneumonia that requires mechanical ventilation and admission to the intensive care unit. The
acute respiratory distress syndrome is associated with a substantial mortality and morbidity
partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are
trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these
drugs may cause super infection or metabolic disorders. Thus, there is a need for a
randomized double blind, placebo controlled trial to define the benefit to risk ratio of
corticosteroids in this patient.
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Terminated
University of Versailles
Phase 3
2010-03-01
The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is
rapidly progressing worldwide and a substantial number of patients get severe H1N1 related
pneumonia that requires mechanical ventilation and admission to the intensive care unit. The
acute respiratory distress syndrome is associated with a substantial mortality and morbidity
partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are
trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these
drugs may cause super infection or metabolic disorders. Thus, there is a need for a
randomized double blind, placebo controlled trial to define the benefit to risk ratio of
corticosteroids in this patient.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
